Moderna receives CHMP opinion recommending Spikevax marketing authorization

Moderna (MRNA) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted an opinion recommending marketing authorization for an updated formulation of the COVID-19 vaccine Spikevax, targeting the SARS-CoV-2 variant LP.8.1, for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals six months of age and older. Following the CHMP’s positive opinion, the European Commission will make a marketing authorization decision on Moderna’s updated COVID-19 vaccine for the 2025-2026 season.